OncoMatch/Clinical Trials/NCT04348747
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
Is NCT04348747 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including Anti-HER2/HER3 Dendritic Cell Vaccine and Pembrolizumab for anatomic stage iv breast cancer ajcc v8.
Treatment: Anti-HER2/HER3 Dendritic Cell Vaccine · Pembrolizumab — This phase IIa trial studies how well dendritic cell vaccines against Her2/Her3 and pembrolizumab work for the treatment of triple negative breast cancer or HER2+ breast cancer or HER+ Breast cancer that has spread to the brain (brain metastasis). Dendritic cell vaccines work by boosting the immune system (a system in the body that protect against infection) to recognize and destroy the cancer cells. . Pembrolizumab is an "immune checkpoint inhibitor" which is designed to either "unleash" or "enhance" the cancer immune responses that already exist by either blocking inhibitory molecules" or by activating stimulatory molecules. Giving dendritic cell vaccines and pembrolizumab may shrink the cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Other
Cancer type
Breast Carcinoma
Tumor Agnostic
Triple-Negative Breast Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
hemoglobin >= 9 g/dl or >= 5.6 mmol/l; leukocytes >= 3 x 10^9/l; anc >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l
Kidney function
creatinine <= 1.5 x uln or crcl/gfr >= 30 ml/min for participant with creatinine levels >1.5 x uln
Liver function
total bilirubin: <= 1.5 x uln or direct bilirubin <= uln for participants with total bilirubin levels > 1.5 x uln; ast/alt <= 2.5 x uln (<= 5 x uln with liver metastases)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
- Roswell Park Cancer Institute · Buffalo, New York
- University of Virginia Comprehensive Cancer Center · Charlottesville, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04348747 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify